Baird Medical signs strategic partnership with Alpmed to co-develop IRE ablation devices
BDMD•Regulatory path and business expansion
Baird Medical will lead global regulatory filings, including the US, with a 510(k) submission targeted by end-2026 and potential clearance in 2027.
The deal broadens Baird Medical’s portfolio beyond its microwave ablation thyroid franchise as it pushes expansion into the US market.
Strategic partnership to co-develop IRE devices
Baird Medical entered a strategic partnership with China-based Alpmed to co-develop and commercialize next-generation irreversible electroporation (IRE) ablation devices globally.
Baird Medical secured worldwide commercialization rights for the first co-developed IRE system aimed at soft-tissue solid tumors.
